Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design

Annals of Oncology

Volumn 26, Issue 10, 2015, Pages 2113-2118

  Gerety, E L ^a   Lawrence, E M ^b   Wason, J ^c   Yan, H ^b   Hilborne, S ^b   Buscombe, J ^a   Cheow, H K ^a   Shaw, A S ^a   Bird, N ^d   Fife, K ^a   Heard, S ^a   Lomas, D J ^a,b   Matakidou, A ^a,b   Soloviev, D ^b   Eisen, T ^a,b   Gallagher, Ferdia A ^a,b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

18F NaF PET CT; 99mTc MDP bone scintigraphy; Bone metastases; Computed tomography; Renal cell carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; SODIUM FLUORIDE F 18;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RADIOLOGIST; SCORING SYSTEM; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BONE TUMOR; CANCER STAGING; FOLLOW UP; KIDNEY TUMOR; METHODOLOGY; MIDDLE AGED; MULTIMODAL IMAGING; PAPILLARY CARCINOMA; PATHOLOGY; PROCEDURES; PROGNOSIS; SCINTISCANNING; SECONDARY; SENSITIVITY AND SPECIFICITY; X-RAY COMPUTED TOMOGRAPHY;

AGED; BONE NEOPLASMS; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIONUCLIDE IMAGING; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84943753935     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv289     Document Type: Article

References (19)

1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society 2014.
2. Woodward E, Jagdev S, McParland L et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone 2011; 48(1): 160-166.
3. Kato S, Murakami H, Takeuchi A et al. Fifteen-year survivor of renal cell carcinoma after metastasectomies for multiple bone metastases. Orthopedics 2013; 26(11):1454-1457.
4. Pal SK, Haas NB. Adjuvant therapy for renal cell carcinoma: past, present and future. Oncologist 2014; 19(8): 851-859.
5. Buhmann Kirchhoff S, Becker C, Duerr HR et al. Detection of osseous metastases of the spine: comparison of high resolution multi-detector-CT with MRI. Eur J Radiol 2009; 69(3): 567-573.
6. Shen G, Deng H, Hu S et al. Comparison of choline-PET/CT, MRI, SPECT and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer:a met-analysis. Skeletal Radiol 2014; 43(11): 1503-1513.
7. Bastawrous S, Bhargava P, Behnia F et al. Newer PET application with an old tracer: role of F-NaF skeletal PET/CT in oncologic practice. Radiographics 2014; 34(5): 1295-1316.
8. Mick CG, James T, Hill JD et al. Molecular imaging in oncology: 18F-sodium fluoride PET imaging of osseous metastatic disease. Am J Roentgenol 2014; 203 (2): 263-271.
9. Hillner BE, Siegel BA, Hanna L et al. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET registry. J Nucl Med 2014; 55(4): 574-581.
10. Hillner BE, Siegel BA, Hanna L et al. Impact of 18F-Fluoride PET on intended management of patients with cancers other than prostate cancer: results from the National Oncologic PET registry. J Nucl Med 2014; 55(7): 1054-1061.
11. Wason J, Jaki T. Optimal design of multi-arm multi-stage trials. Stat Med 2012; 31: 4269-4279.
12. Wason JM, Stecher L, Mander AP. Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?. Trials 2014;15: 364.
13. Yoon SH, Kim KS, Kang SY et al. Usefulness of 18F-fluoride PET/CT in breast cancer patients with osteosclerotic bone metastases. Nucl Med Mol Imaging 2013; 47(1): 27-35.
14. Ota N, Kato K, Iwano S et al. Comparison of 18F-fluoride PET/CT, 18F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study. Br J Radiol 2014; 87(1034):20130444.
15. Shvarts O, Lam JS, Kim HL et al. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol 2004; 172(3):867-870.
16. Bhargava P, Hanif M, Nash C. Whole body F-18 sodium fluoride PET-CT in a patient with renal cell carcinoma. Clin Nucl Med 2008; 33(12): 894-895.
17. Fuccio C, Spinapolice EG, Cavalli C et al. 18F-fluoride PET/CT in the detection of bone metastases in clear cell renal cell carcinoma: discordance with bone scintigraphy. Eur J Nucl Med Mol Imaging 2013; 40(12): 1930-1931.
18. Sharma P, Karunanithi S, Chakraborty PS et al. 18F-Fluoride PET/CT for detection of bone metastasis in patients with renal cell carcinoma: a pilot study. Nucl Med Commun 2014; 35(12): 1247-1253.
19. Ballinger JR. Short- and long-term responses to molybdenum-99 shortages in nuclear medicine. Br J Rad 2010;83: 899-901.